Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue
Net product sales	$ 89,571	$ 11,552
Revenue from royalty agreement	30,000
Licensing revenue	2,474	467	1,480
Total revenue	122,045	12,019	1,480
Costs and expenses
Cost of product sales	5,758	1,104
Research and development	19,586	17,245	23,517
Selling, general and administrative	72,471	55,590	20,132
Total costs and expenses	97,815	73,939	43,649
Operating income (loss)	24,230	(61,920)	(42,169)
Other income (expense)
Interest income	348	299	120
Interest expense	(4,963)	(7,849)	(3,575)
Changes in fair value of derivative liabilities	2,809	(13,354)	(710)
Loss on extinguishment of debt	(2,592)	(9,550)
Other income	39	101	50
Total other income (expense)	(4,359)	(30,353)	(4,115)
Net income (loss)	19,871	(92,273)	(46,284)
Cumulative dividends on Series A convertible preferred stock			(1,143)
Net income (loss) attributable to common stockholders	$ 19,871	$ (92,273)	$ (47,427)
Income (loss) per common share:
Basic	$ 0.47	$ (2.90)	$ (2.72)
Diluted	$ 0.32	$ (2.90)	$ (2.72)
Weighted-average number of common shares:
Basic (in shares)	42,260,896	31,848,299	17,440,910
Diluted (in shares)	50,583,511	31,848,299	17,440,910